EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)

Helio S Sader iD, Rodrigo E Mendes iD, Cecilia G Carvalhaes iD, John H Kimbrough iD, Mariana Castanheira iD

Open Forum Infectious Diseases · 03.02.2023 · 10 (2)

DOI: 10.1093/ofid/ofad046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 31.01.2023. Verfasst von Helio S Sader und 4 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories, North Liberty, Iowa, USA. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As the frequency of metallo-β-lactamase (MBL)-producing Enterobacterales is increasing worldwide, effective antimicrobials to treat the infections caused by these organisms are urgently needed.

Methods

The activity of aztreonam-avibactam and comparators were evaluated against 27 834 Enterobacterales isolates collected from 74 US medical centers in 2019–2021. Isolates were susceptibility tested by broth microdilution. An aztreonam-avibactam pharmacokinetic/pharmacodynamic breakpoint of ≤8 mg/L was applied for comparison. Antimicrobial susceptibility and the frequency of key resistance phenotypes were assessed then stratified by year and infection type. Carbapenem-resistant Enterobacterales (CRE) were screened for carbapenemase (CPE) genes by whole genome sequencing.

Results

Aztreonam-avibactam inhibited >99.9% of Enterobacterales at ≤8 mg/L. Only 3 isolates (0.01%) had an aztreonam-avibactam minimum inhibitory concentration (MIC) >8 mg/L. The CRE rates were 0.8%, 0.9%, and 1.1% in 2019, 2020, and 2021, respectively; 99.6% (260 of 261) of CRE isolates were inhibited at an aztreonam-avibactam MIC of ≤8 mg/L. The CRE susceptibility to meropenem-vaborbactam decreased from 91.7% in 2019 to 83.1% in 2020 and 76.5% in 2021 (82.1% overall). The CRE, multidrug-resistant, and extensively drug-resistant phenotypes were markedly higher among isolates from pneumonia compared with other infections. The most common carbapenemase among CRE was Klebsiella pneumoniae carbapenemase (65.5% of CRE), followed by New Delhi metallo-β-lactamase (11.1%), oxacillinase (OXA)-48-like (4.6%), Serratia marcescens enzyme (2.3%), and imipenemase (1.5%). Among non-CPE-producing CRE isolates (n = 44; 16.9% of CRE), 97.7% were inhibited at ≤8 mg/L aztreonam-avibactam and 85.4% were meropenem-vaborbactam susceptible.

Conclusions

The frequencies of MBL and OXA-48-type producers increased markedly. Aztreonam-avibactam demonstrated potent and consistent activity against Enterobacterales across infection types and over time.

Schlagwörter

Stichwörter der Autor:innen

CREbeta-lactamase inhibitorcarbapenemasemetallo-beta-lactamase

Autor:innen und Institutionen

  • JMI Laboratories, North Liberty, Iowa, USA.

ORCID-Profile: Helio S Sader, Rodrigo E Mendes, Cecilia G Carvalhaes, John H Kimbrough, Mariana Castanheira

Förderung

  • AbbVie

Zitieren

APA

Sader, H. S., Mendes, R. E., Carvalhaes, C. G., Kimbrough, J. H., & Castanheira, M. (2023). Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021). Open Forum Infectious Diseases, 10(2). https://doi.org/10.1093/ofid/ofad046

Vancouver

Sader HS, Mendes RE, Carvalhaes CG, Kimbrough JH, Castanheira M. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021). Open Forum Infectious Diseases. 2023;10(2). doi:10.1093/ofid/ofad046

BibTeX
@article{Sader2023,
  author = {Sader, Helio S and Mendes, Rodrigo E and Carvalhaes, Cecilia G and Kimbrough, John H and Castanheira, Mariana},
  title = {Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {2},
  doi = {10.1093/ofid/ofad046}
}
Kostenlos starten →